269 research outputs found
Response to Galassi et al, "A 5-Year Experience of Benign Pancreatic Hyperenzymemia"
No full textclinical aspect of pancreatic hyperenzymemi
Autoimmune pancreatitis: a challenging diagnostic puzzle for clinicians.
No full textAutoimmune pancreatitis is a form of pancreatitis with autoimmune stigmata that may present as either focal or diffuse gland involvement. In focal forms, autoimmune pancreatitis shares demographic, clinical, biochemical and imaging features with pancreatic cancer. Since autoimmune pancreatitis is a benign disease and steroid therapy can rapidly resolve symptoms, improve radiological findings and avoid unnecessary surgery, the current clinical challenge is how to differentiate autoimmune pancreatitis from pancreatic neoplasia. Even though definitive diagnosis of the disease is difficult, several diagnostic criteria have been proposed and progress has been made in imaging studies. The management of this unique form of pancreatitis should, therefore, be handled in centres with knowledge of all aspects of the disease. This article briefly reviews clinical aspects of autoimmune pancreatitis with a focus on its diagnostic imaging and management
Le malattie autoimmuni
No full textAspetti patologici, criteri diagnostici, epidemiologia e manifestazioni cliniche; imaging e terapia della pancreatite autoimmun
Modellazione numerica e analisi sperimentale del processo di polimerizzazione frontale per una resina epossidica
No full text
Faecal elastase-1 is an independent predictor of survival in advanced pancreatic cancer.
No full textBACKGROUND:The relationship between prognosis of advanced pancreatic cancer and exocrine secretion impairment is unknown.AIM:To investigate a possible correlation between faecal elastase-1 value and survival in advanced pancreatic cancer.METHODS:194 patients with advanced pancreatic cancer were prospectively enrolled between 2007 and 2009 and underwent faecal elastase-1 measurement. Exocrine pancreatic secretion was defined as "moderately reduced" (faecal elastase-1: 100-200μg/g), "severely reduced" (faecal elastase-120μg/g) and "extremely reduced" (faecal elastase-1≤20μg/g).RESULTS:Median faecal elastase-1 was 204μg/g (interquartile range 19; 489). Overall, 48 patients (25%) had an extremely reduced exocrine pancreatic secretion, 28 (14%) a severely reduced exocrine pancreatic secretion and 21 (11%) a moderately reduced exocrine pancreatic secretion. Patients with extremely reduced exocrine pancreatic secretion had higher rates of pancreatic head localizations (P<0.01) and of jaundice (P<0.01). Median overall survival was 10.5months. Patients with faecal elastase-1≤20μg/g had a worse prognosis (median survival: 7 versus 11months, P=0.031). Presence of metastases (Hazard ratio 1.81, P<0.0001), haemoglobin≤12g/L (Hazard ratio 2.12, P=0.001), albumin≤40g/L (Hazard ratio 1.64, P=0.010) and FE-1≤20μg/g (Hazard ratio 1.59 P=0.023) resulted as independent predictors of survival in advanced pancreatic cancer patients.CONCLUSIONS:A low value of faecal elastase-1 is strongly correlated with a poor survival in advanced pancreatic cancer
- …
